ATF3 promotes death receptor 5 (DR5) induction and apoptotic cell death upon zerumbone (a bioactive sesquiterpene) or celecoxib (a selective inhibitor of cyclooxygenase 2) treatment in human p53-deficient colorectal cancer cells (89). This evidence concerns the gene TP53 and colorectal cancer.